309 related articles for article (PubMed ID: 23291982)
1. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
Pires MM; Hopkins BD; Saal LH; Parsons RE
Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
[TBL] [Abstract][Full Text] [Related]
2. The multi-hit hypothesis in basal-like breast cancer.
Dent P
Cancer Biol Ther; 2013 Sep; 14(9):778-9. PubMed ID: 23974512
[TBL] [Abstract][Full Text] [Related]
3. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
4. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
5. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.
Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ
J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332
[TBL] [Abstract][Full Text] [Related]
6. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
Wendt MK; Williams WK; Pascuzzi PE; Balanis NG; Schiemann BJ; Carlin CR; Schiemann WP
Neoplasia; 2015 Jan; 17(1):124-33. PubMed ID: 25622905
[TBL] [Abstract][Full Text] [Related]
7. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
[TBL] [Abstract][Full Text] [Related]
8. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
9. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.
Kim G; Ouzounova M; Quraishi AA; Davis A; Tawakkol N; Clouthier SG; Malik F; Paulson AK; D'Angelo RC; Korkaya S; Baker TL; Esen ES; Prat A; Liu S; Kleer CG; Thomas DG; Wicha MS; Korkaya H
Oncogene; 2015 Feb; 34(6):671-80. PubMed ID: 24531711
[TBL] [Abstract][Full Text] [Related]
10. Stromal PTEN determines mammary epithelial response to radiotherapy.
Sizemore GM; Balakrishnan S; Thies KA; Hammer AM; Sizemore ST; Trimboli AJ; Cuitiño MC; Steck SA; Tozbikian G; Kladney RD; Shinde N; Das M; Park D; Majumder S; Krishnan S; Yu L; Fernandez SA; Chakravarti A; Shields PG; White JR; Yee LD; Rosol TJ; Ludwig T; Park M; Leone G; Ostrowski MC
Nat Commun; 2018 Jul; 9(1):2783. PubMed ID: 30018330
[TBL] [Abstract][Full Text] [Related]
11. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
[TBL] [Abstract][Full Text] [Related]
13. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
[TBL] [Abstract][Full Text] [Related]
14. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and
the correlation among them].
Li X; Wang Q; Fu L; Liu M; Yu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
[TBL] [Abstract][Full Text] [Related]
15. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
[TBL] [Abstract][Full Text] [Related]
16. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
[TBL] [Abstract][Full Text] [Related]
17. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
[TBL] [Abstract][Full Text] [Related]
18. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
19. Metformin and erlotinib synergize to inhibit basal breast cancer.
Lau YK; Du X; Rayannavar V; Hopkins B; Shaw J; Bessler E; Thomas T; Pires MM; Keniry M; Parsons RE; Cremers S; Szabolcs M; Maurer MA
Oncotarget; 2014 Nov; 5(21):10503-17. PubMed ID: 25361177
[TBL] [Abstract][Full Text] [Related]
20. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
Liu JC; Voisin V; Wang S; Wang DY; Jones RA; Datti A; Uehling D; Al-awar R; Egan SE; Bader GD; Tsao M; Mak TW; Zacksenhaus E
EMBO Mol Med; 2014 Dec; 6(12):1542-60. PubMed ID: 25330770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]